+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 14Years +
All Genders
ID07167329

BELIEVE-VHL Study on Belzutifan Treatment and Genetics in Von Hippel-Lindau Syndrome

Led by José Claudio Casali da Rocha · Updated on 2025-09-11

100

Participants Needed

1

Research Sites

204 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating the use of belzutifan, a HIF2 inhibitor, in people with von Hippel-Lindau VHL syndrome, a condition that causes tumors to grow in different parts of the body. This Phase 2 trial aims to evaluate how belzutifan affects tumors, its benefits, possible side effects, timing of treatment response, and disease progression in a real-world setting. The study also explores genetic factors influencing treatment response and conducts a pharmacoeconomic analysis to understand the impact on healthcare costs. Participants with VHL syndrome who have measurable or progressive tumors will receive oral belzutifan. The study monitors hemoglobin and erythropoietin levels during the first six months, assessing the need for erythropoietin supplements in cases of anemia, fatigue, or low oxygen. It also evaluates patient quality of life and perceptions regarding VHL syndrome using questionnaires. The treatment period includes up to 104 weeks of follow-up for tumor response and side effects. Throughout the study, participants will undergo regular assessments including tumor imaging by RECIST 1.1 criteria, blood tests for hemoglobin and erythropoietin, and quality-of-life questionnaires over two years. Researchers will track anemia incidence, need for blood transfusions, and the effects of erythropoietin supplementation on tumor growth. The trial also includes a retrospective and prospective economic evaluation based on healthcare costs before and after starting belzutifan.

CONDITIONS

Brief Title

Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial

Research Team

J

José Claudio Casali da Rocha, Head of Oncogenetics

J

José Reinaldo De Oliveira Junior

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here